Glass House Brands (GLAS) Income from Non-Controlling Interests (2022 - 2026)
Glass House Brands' (GLAS) quarterly Income from Non-Controlling Interests came in at $126000.0 in Q1 2026, down 73.42% on a QoQ basis from $474000.0 in Q4 2025.
Glass House Brands (GLAS) Income from Non-Controlling Interests (2022 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 5 years of Income from Non-Controlling Interests data on file, last reported at $126000.0 in Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests changed N/A year-over-year to $126000.0 in Q1 2026; TTM through Mar 2026 was $781000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $707000.0, up 250.0% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at $126000.0, down from $474000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for GLAS reached as high as $100.4 billion in Q2 2023 and fell as low as -$24.0 billion in Q2 2022.
- Historically, Income from Non-Controlling Interests has averaged $5.1 billion across 5 years, with a median of $62528.0 in 2023.
- Across the five-year window, Income from Non-Controlling Interests jumped 1327.61% in 2023 and slumped 211.95% in 2024, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at -$8071.0 in 2022, then soared by 1327.61% to $99080.0 in 2023, then surged by 295.64% to $392000.0 in 2024, then advanced by 20.92% to $474000.0 in 2025, then plunged by 73.42% to $126000.0 in 2026.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were $126000.0 in Q1 2026, $474000.0 in Q4 2025, and $106000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | 126,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 126,000.00 |
| Dec 31, 2025 | 474,000.00 |
| Sep 30, 2025 | 106,000.00 |
| Jun 30, 2025 | 75,000.00 |
| Dec 31, 2024 | 392,000.00 |
| Sep 30, 2024 | -70,000.00 |
| Jun 30, 2024 | 43,000.00 |
| Dec 31, 2023 | 99,080.00 |
| Sep 30, 2023 | 62,528.00 |
| Jun 30, 2023 | 100.41 Bn |
| Mar 31, 2023 | -37,000.00 |
| Dec 31, 2022 | -8,071.00 |
| Sep 30, 2022 | -7,044.00 |
| Jun 30, 2022 | -23.96 Bn |
| Mar 31, 2022 | -22,596.00 |